Navigation Links
CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
Date:1/21/2013

disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for people with hemophilia deficiency is to treat by replacement factor therapy.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company with headquarters in Melbourne, Australia. For more information visit http://www.cslbehring.com. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

Media Contact:
Sheila A. Burke

Director, Worldwide Commercial Operations Communications & Public Relations
CSL Behring
610-878-4209


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
2. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
3. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
4. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
5. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
6. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
7. Bottom-up approach provides first characterization of pyroelectric nanomaterials
8. First Bedside DNA Test to be Distributed by Chirus in UK
9. First Maryland Hospital Offering 3D Mammograms? VA Maryland Health Care System
10. BioTechniques Announces the Publication of 'Transfection' – The First Issue of a New, Digital-Only Spotlight Series
11. Dallas-Fort Worth Fertility Associates Celebrates First Birth in North Texas from Advanced Trophectoderm Biopsy Screening Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ) has ... Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... traces its roots in the latter half of ... went unexplored and unfulfilled for several decades owing ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... , ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) and ... entered into a licensing agreement for antibody therapeutic rights under ... Under the terms of the agreement, Affitech will license exclusive ...
... , ROCKVILLE, Md., July 22 ... selection of a Respiratory Syncytial Virus (RSV) vaccine candidate that ... Investigational New Drug (IND) application. As previously announced, Novavax ... of which have successfully induced antibody responses in mice. ...
... , , , ... Biotech, Inc., a company personalizing spine care through the development ... that they have entered into a collaboration that allows Axial ... Population Database (UPDB). UPDB is a genealogical and family history ...
Cached Biology Technology:Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 2Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 3Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 4Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 5Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 2Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 3Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 4Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 2Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 3
(Date:7/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) ... Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, ... report to their offering ... Touch-Less Sensing Market to Grow Exponentially. Touch-less sensing ... the companies were unable to leverage this technology ...
(Date:7/10/2014)... 2014 Fingerprint Cards, (FPC,s) ... win (DW). An Asian OEM has selected FPC1021 for a ... in August 2014.   FPC is proud to ... a planned date for start of mass production in August ... SEK 5M, for delivery in the first half of July. ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family Melastomataceae ... the family rely on bees for their pollination. Only about ... vertebrates. The flowers of Axinaea appear in clusters ... of the different species are pink, yellow, orange or red. ... contrasting colours of their bulbous appendages. The pollination mechanism of ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2Novel type of bird pollination mechanism discovered in South America 2
... ... Presidential Early Career Award for Scientists and Engineers (PECASE). The award ... scientists and engineers in the early stages of their careers. ... significant award," said Jane Lubchenco, Ph.D., under secretary of commerce for ...
... Researchers at the University of Missouri have identified a ... may provide new insight into the debilitating and fatal ... "Critical communication occurs at the point where nerves and ... nerves and muscles is disrupted, muscles do not work ...
... -- The National Institutes of Health (NIH) has awarded a ... research into risk factors for spina bifida and related congenital ... or brain is not fully enclosed. The research will ... E. Mason at Weill Cornell Medical College. Dr. Ross is ...
Cached Biology News:President to honor high achieving, early career NOAA scientists 2MU researchers find new insight into fatal spinal disease 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 3
...
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
Biology Products: